Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6174939 | European Urology | 2016 | 5 Pages |
Abstract
After the introduction of systemic targeted therapies, the use of nephrectomy in patients with metastatic renal cell carcinoma has declined. Currently, systemic therapy is offered to more patients first as a means to select those candidates that will likely benefit from removal of their primary tumour. Although studies consistently demonstrate a survival benefit after nephrectomy, most patients with poor risk metastatic disease are unlikely to benefit from surgery. Soon studies will report on the effect of nephrectomy in patients with metastatic disease at diagnosis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Axel Bex, Börje Ljungberg, Hein van Poppel, Thomas Powles, on behalf of the European Association of Urology on behalf of the European Association of Urology,